RxDoctor Payments Data

Joanna Silva

Family · El Paso, TXNPI 1023682861

Payments from drug & device makers

$808in general payments, 2019–2025

Across 31 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • Corcept Therapeutics$125
  • AbbVie$125
  • Lilly USA, LLC$66
  • Otsuka America Pharmaceutical, Inc.$56
  • Amgen$44
  • plus $177 from 7 others

What the payments were for

  • Food & beverage$808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$201,662
Medicare patients
125
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$36,157
MyrbetriqMirabegron41$9,328
XareltoRivaroxaban29$8,759
FarxigaDapagliflozin Propanediol21$7,881
CreonLipase/Protease/Amylase18$7,104
EntrestoSacubitril/Valsartan21$7,084
KerendiaFinerenone19$6,154
JardianceEmpagliflozin20$6,005
JanuviaSitagliptin Phosphate19$5,858
NamzaricMemantine Hcl/Donepezil Hcl19$5,505
Levothyroxine Sodium228$2,545
Gabapentin261$2,499
Midodrine Hcl40$2,420
Sertraline Hcl185$2,397
Mirtazapine168$2,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Namzaric$125$12,60937 claims
AstraZenecaFarxiga$39$7,88121 claims
NovartisEntresto$36$7,08421 claims
BayerKerendia$24$6,15419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →